MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge a number of intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial goals had been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, when among the https://ericht999gsw0.59bloggers.com/profile